ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis?

  • Toshifumi Yamaguchi
  • Atsuo TakashimaEmail author
  • Narikazu Boku
ASO Author Reflections



Dr. Boku reports support from Ono and Taiho (research grant, honorarium) and from Bristol-Myers Squibb, Chugai, and Eli-Lilly (honorarium). The other authors report no conflicts of interest.


  1. 1.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 3rd English edition. Gastric Cancer. 1998;1:10–24.CrossRefGoogle Scholar
  2. 2.
    Kodera Y, Ito S, Mochizuki Y, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15(3):335–7.CrossRefGoogle Scholar
  3. 3.
    Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215–21.CrossRefGoogle Scholar
  4. 4.
    Yamaguchi T, Takashima A, Nagashima K, et al. Efficacy of postoperative chemotherapy after resection that leaves no macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): A multicenter retrospective study. Ann Surg Oncol. 2019. CrossRefPubMedGoogle Scholar
  5. 5.
    Nakayama I, Chin K, Matsushima T, Takahari D, et al. Retrospective comparison of S 1 plus cisplatin versus S 1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. Int J Clin Oncol. 2017;22:1060–8.CrossRefGoogle Scholar
  6. 6.
    Kano Y, Kosugi S, Ishikawa T, et al. Prognostic significance of peritoneal lavage cytology at three cavities in patients with gastric cancer. Surgery. 2015;158(6):1581–9.CrossRefGoogle Scholar
  7. 7.
    Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). 2018 ASCO Annual Meeting, J Clin Oncol. 2018;36(suppl; abstr 4046).Google Scholar
  8. 8.
    Manzanedo I, Pereira F, Rihuete Caro C et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019;26:2615–21.CrossRefGoogle Scholar
  9. 9.
    Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922–9.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Toshifumi Yamaguchi
    • 1
    • 2
  • Atsuo Takashima
    • 2
    Email author
  • Narikazu Boku
    • 2
  1. 1.Cancer Chemotherapy Center and Second Department of Internal MedicineOsaka Medical CollegeOsakaJapan
  2. 2.Gastrointestinal Oncology DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations